The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

Skip to main content

Hepatitis Monitoring and Treatment

Hepatitis monitoring and treatment — current antiviral therapy and liver follow-up process for chronic hepatitis B and C.

Structured care process in chronic hepatitis B and C infections that includes monitoring of liver function, measurement of viral load, and administration of antiviral therapy.

Indication

  • Patients found to have chronic hepatitis B (HBsAg positivity)
  • Patients found to have chronic hepatitis C (HCV RNA positivity)
  • Persistent elevation of liver enzymes (ALT/AST)
  • Patients found to have advanced fibrosis on liver biopsy or elastography
  • Individuals at risk of cirrhosis or liver cancer due to hepatitis virus
  • Follow-up of infants born to hepatitis B carrier mothers
  • Reactivation risk assessment in patients who will receive immunosuppressive therapy

Preparation

  • At the initial assessment, complete blood count, liver function tests, and viral load (HBV-DNA / HCV-RNA) are measured
  • The level of fibrosis is assessed with liver ultrasound and elastography (FibroScan)
  • Viral genotyping is performed before hepatitis C treatment
  • Pregnancy status and other concurrent medications should be reported to the physician before starting treatment
  • Vaccination status (hepatitis A) is reviewed

How it's performed

  1. In hepatitis B, oral antivirals (entecavir, tenofovir) are generally used for the long term in suitable cases
  2. In hepatitis C, treatment with direct-acting antivirals (DAA) is most often given for 8-12 weeks
  3. Regular blood tests and viral load monitoring are performed throughout treatment
  4. Side effects and treatment response are evaluated through periodic check-ups
  5. In cirrhotic patients, liver ultrasound and AFP-based cancer screening are performed every 6 months

Post-procedure

  • After hepatitis C treatment, HCV-RNA is measured at week 12 to assess sustained virologic response (SVR12)
  • In hepatitis B, viral load, ALT, and HBeAg/anti-HBe follow-up is continued every 3-6 months
  • In the presence of advanced fibrosis or cirrhosis, lifelong follow-up is planned
  • Hepatitis B screening and vaccination of family members is recommended
  • Lifestyle recommendations regarding alcohol, hepatotoxic medications, and obesity are provided

Risks

  • Nausea, fatigue, or headache due to antiviral medications
  • Risk of flare on early discontinuation of hepatitis B treatment
  • Rare drug interactions in hepatitis C treatment (especially with cardiac and cholesterol medications)
  • Variable treatment response in patients with advanced liver disease
  • Persistent risk of liver cancer in cirrhotic patients even when treatment is successful

FAQ

Can hepatitis C be completely treated?

With direct-acting antivirals (DAAs), sustained virologic response is achieved in the great majority of hepatitis C patients. However, liver follow-up is still required in advanced cirrhosis.

How long are hepatitis B medications used?

In hepatitis B, antiviral therapy is generally long term; some patients may require use for years or even lifelong. The duration is determined by the physician.

Can the hepatitis virus be transmitted to family members?

Hepatitis B can be transmitted through blood, sexual contact, and from mother to baby. Hepatitis C is transmitted mainly through blood. Screening of family members and the hepatitis B vaccine for those who are eligible are recommended.

Can I drink alcohol during treatment?

No. Alcohol can increase liver damage and viral load and reduce treatment success; it is not recommended during or after treatment.

Related Medical Services

Other services in the same specialty or with similar indications you may want to explore.